This article provides general legal information. It is not legal advice. Laws vary by state. Facts matter too. Reading this page does not create an attorney-client relationship. For advice about your specific situation, consult a licensed attorney in your state.
A Depo-Provera brain tumor lawsuit usually centers on two claims. First, long-term use has been linked in studies and lawsuits to meningioma growth. The drug is depot medroxyprogesterone acetate, an injectable birth control drug. Second, users argue they did not get strong enough warnings soon enough. For many people, the issue becomes urgent after a scan, a surgery consult, or a diagnosis that may explain headaches, vision changes, memory problems, or seizures. At that point, the legal questions can feel overwhelming: Is there really a case? Is there an active federal court case? Is there still time to act?
As of May 21, 2026, there is active federal MDL litigation over Depo-Provera. It is in the Northern District of Florida. JPML's May 1, 2026 statistics report lists 3,769 pending actions in MDL No. 3140. The current FDA/DailyMed label for Depo-Provera CI also includes meningioma warning language. That warning language followed FDA's December 2025 approval of supplement labeling for Depo-Provera CI and Depo-SubQ Provera 104. At the same time, the studies point to a possible link, not automatic proof that the drug caused any one tumor. That means every case still depends on records. Timing, diagnosis facts, expert proof, and state law matter too.
This guide explains the issue in plain English. It covers what the Depo-Provera lawsuits are about, who may qualify, what damages may be available, and what deadlines matter. You will also see how the medical evidence is being used and which steps can help protect a claim. If you want a fast screening path while gathering records, start with Do I Qualify? .
What Is a Depo-Provera Brain Tumor Lawsuit?
The Depo-Provera brain tumor lawsuit is a product liability claim. Product liability means a claim that a product was unsafe or lacked proper warnings. These cases focus on depot medroxyprogesterone acetate, often called DMPA. Lawyers are reviewing whether DMPA is linked to meningioma growth and whether drug makers warned patients and prescribers in time. A meningioma is a tumor that forms in the membranes around the brain and spinal cord. Many meningiomas are called benign, but benign does not mean harmless. Location matters. A tumor can still cause brain and nerve problems. It can also lead to surgery, radiation, lasting limits, or more than one of those harms.
The current Pfizer patient information says women who use Depo-Provera CI may have a possible increased risk for growth of a meningioma. It also tells patients to inform their healthcare professional if they have a meningioma or had one in the past. That matters because warnings often become a major issue in drug lawsuits. A changed or stronger warning does not prove liability by itself. But it can become part of the timeline lawyers review: what the company knew, when it knew it, and whether the label warned people clearly enough.
A federal panel put Depo-Provera product liability cases into MDL No. 3140 in the U.S. District Court for the Northern District of Florida. The court's MDL page says the cases share fact questions, including whether Depo-Provera causes meningioma, whether defendants knew of the alleged risk, and whether defendants failed to warn or promote safer choices. The MDL lets one judge handle shared discovery and key motions. Each plaintiff still needs proof for her own claim.
What Is the Current Status of the Depo-Provera Litigation?
As of May 21, 2026, the litigation is active. It is still in a pretrial stage, not a final-resolution stage. The JPML May 1, 2026 MDL statistics report lists 3,769 pending actions in MDL No. 3140, with 3,835 total historical actions. On the Northern District of Florida's Depo-Provera MDL orders and hearing page , the court lists case-management conferences from May 15 through December 18, 2026. It also lists a June 24-26, 2026 Rule 702 motions hearing. Rule 702 fights matter because they address expert testimony. The court looks at whether that testimony is reliable enough to be heard. In mass tort litigation, those rulings often shape settlement talks. They can also affect whether cases move toward bellwether trials.
That means the litigation is still in a proof-building phase. Plaintiffs' lawyers are building scientific evidence and company-record evidence. Defendants are still contesting causation and warning issues, while the court manages the pretrial process. The June 2026 expert hearing may be important, but it will not by itself prove that Depo-Provera caused any one person's tumor. People looking for a simple yes-or-no settlement answer usually will not find one yet. No article should promise a payout, a settlement amount, or an outcome.
If you were diagnosed after using Depo-Provera, do not wait for a headline about a global resolution. Waiting can create statute-of-limitations problems, and those deadline rules vary by state. A licensed attorney can review where your claim may belong. It may fit in the federal MDL, state court, or another track. The answer depends on where you used the drug, when you were diagnosed, and which defendants are involved.
If you want to organize the basics first, the Do I Qualify? assessment can help you gather the dates, drug history, and diagnosis details lawyers usually ask for at intake.
Who May Qualify for a Depo-Provera Lawsuit?
Qualification is not based on one checklist that applies in every state. Still, most screened claims share the same basic facts. They usually need records showing Depo-Provera use and a later meningioma diagnosis or treatment. Timing must be able to support causation, and the claim must still be timely. Many firms look closely at length of use because the studies and current lawsuit claims focus more on longer or repeated exposure than on one isolated injection.
Records that often matter include pharmacy records, clinic charts, injection logs, insurance records, MRI or CT reports, pathology reports, and neurosurgery records. Notes showing when symptoms first appeared can also matter. If surgery was done, operative reports and pathology can become important. If there was no surgery, imaging and specialist notes may still support the diagnosis and treatment history.
People often ask whether they need proof that Depo-Provera was the only possible cause. Usually, the legal question is more specific. Product liability cases often ask whether the drug was a substantial contributing factor, whether warnings were adequate, and whether qualified experts can support the claim. Other health conditions do not automatically defeat a case, but they do affect the causation review.
A claimant may be in a stronger screening position when the facts include the following.
- Extended or repeated Depo-Provera use documented by medical or pharmacy records.
- A diagnosed meningioma, brain tumor surgery, radiation treatment, or ongoing neurological follow-up.
- Symptoms, imaging, or diagnosis dates that can be tied to a specific timeline.
- Residence in a state where the filing deadline may still be open under the rule that applies.
Because qualification rules depend on the case, talk with a licensed attorney in your state as soon as possible. That is especially important if you were diagnosed years after you stopped receiving injections. Cases with hidden injuries often involve discovery-rule arguments and state-specific exceptions.
What Medical Evidence Is Being Used in These Cases?
Two sources may appear often in case reviews. First, a 2024 BMJ national case-control study looked at some progestogens, including injectable medroxyprogesterone acetate. It reported increased risk of meningioma requiring surgery with prolonged use. The study's discussion is careful. Still, it gave plaintiffs a peer-reviewed article about the same drug family involved in the lawsuits.
Second, a 2025 JAMA Neurology study found that women receiving DMPA had a greater risk of later meningioma diagnosis. The link was stronger with prolonged exposure and in women who started at older ages. The authors and later correspondence stress a key legal point too: the study shows association, not automatic proof of causation. Courts and experts will still debate study methods, other possible causes, dose, how the drug may work in the body, and each plaintiff's facts.
Official labels and notices matter too. The official DailyMed Depo-Provera CI label was updated in December 2025 to add meningioma language. The update included warnings and precautions about reported cases after repeated use. It focused mainly on long-term use. In Europe, an EMA direct healthcare professional communication also addressed the drug and meningioma risk. Plaintiffs may point to those materials and argue that risk information became stronger over time. Defendants may respond that warning language changed as evidence developed and that the science remains contested. Neither the label update nor the European notice proves causation in any one case by itself.
What Did the FDA Label Change Add About Meningioma Risk?
FDA's December 12, 2025 supplement approval letter for Depo-Provera CI and Depo-SubQ Provera 104 approved prior-approval supplements for NDA 020246/S-074 and NDA 021583/S-045. The letter acknowledges a June 12, 2025 amendment, but the approval was effective on the date of the December 12, 2025 letter. The letter says the approved supplement added information related to meningioma risk in Section 5 Warnings and Precautions, Section 17 Patient Counseling Information, and the corresponding patient-information sections. In practical terms, that makes the FDA approval letter an important primary source for the warning timeline.
A label change is not the same thing as a finding that every meningioma was caused by Depo-Provera. It also does not decide whether earlier warnings were legally adequate. Those questions are still being litigated and may depend on expert testimony, prescribing records, state law, and the facts of each claimant's exposure. Still, the FDA approval letter helps explain why attorneys are focusing on warning dates, repeated use, and what patients and prescribers were told over time.
What Compensation May Be Available?
No article can honestly predict what any one Depo-Provera claimant will recover. Compensation depends on proof, state law, injury severity, future outlook, and whether the case settles or goes to trial. Still, the main damage categories are common in product liability cases. They can help readers understand what a lawyer reviews.
- Past medical costs, such as scans, surgery, hospital care, follow-up visits, drugs, or radiation.
- Future medical costs if monitoring, treatment, or more care is expected.
- Lost wages or reduced earning power if symptoms, surgery, or recovery limited work.
- Pain and suffering, emotional distress, and loss of normal life depending on state law.
- Wrongful death damages for surviving family members where the facts and state statutes allow them.
Punitive damages may also be alleged in some states. They are not available in every case and are heavily controlled by state law. Be cautious about any source that claims a guaranteed average payout or fixed settlement range this early in the litigation. Those claims are usually marketing language, not dependable legal guidance.
What Is the Filing Deadline for a Depo-Provera Claim?
The statute of limitations, meaning the deadline to file a lawsuit, is one of the most important parts of any mass tort claim. It also varies sharply by state. Some states start the clock when the injury occurred. Others use a discovery rule, which can move the start date to when the injury was found or reasonably should have been found. Drug injury cases with slow-growing tumors often raise hard questions about that date.
Examples from official state-law sources show why timing cannot be guessed.
- California generally gives two years for injury claims under Code of Civil Procedure section 335.1 .
- Florida generally places negligence actions in a two-year category under section 95.11 . The same section separately lists a four-year period for some injury claims based on personal property. That rule covers injury based on the design, manufacture, distribution, or sale of personal property. It does not apply to property permanently built into real property. Timing in a product liability case can still require attorney review. So can accrual, which means when the legal clock starts.
- New York generally provides three years for personal injury under CPLR section 214 . Latent-exposure claims may involve CPLR section 214-c . That section addresses injury caused by latent effects of exposure to a substance.
These examples are only illustrations, not personal deadline advice. Choice-of-law questions, tolling rules, wrongful-death rules, and discovery-rule disputes can all change the real deadline. If you think Depo-Provera may be connected to a meningioma diagnosis, do not rely on internet estimates alone. Talk with a licensed attorney in your state before assuming you have time.
How Do You File a Depo-Provera Claim?
Filing a claim usually starts well before a complaint is formally filed in court. Stronger cases are often built through careful intake and document collection first.
- Write down a clean timeline with first use, last use, symptom onset, imaging dates, diagnosis dates, and surgery or treatment dates.
- Request records from clinics, pharmacies, imaging centers, neurosurgeons, hospitals, and insurers.
- Preserve proof of out-of-pocket losses, missed work, and ongoing symptoms.
- Speak with counsel who knows mass tort drug litigation, so the case can be screened for venue, deadline, and causation issues.
- If the claim is accepted, counsel may file in federal or state court depending on the facts and procedural strategy.
Why Do State Law and Proof Details Matter So Much?
Two Depo-Provera cases can look similar at first. They can move very differently once lawyers review the governing law. One state may apply a different discovery-rule standard. Another may treat punitive damages more narrowly, limit wrongful-death beneficiaries, or use different rules for expert proof. The learned-intermediary doctrine can also vary. That doctrine focuses on the warnings given to prescribing clinicians. That is why mass tort ads often sound broad while real case review is much more specific.
Proof details matter just as much. Complete injection records, dated imaging, pathology, work-loss documents, and a clear symptom timeline can all help. Memory alone is weaker. Missing records do not always end a case, but they can make timing disputes harder. In a meningioma case, even a few months can matter. The defense may argue the injury should have been found earlier or that another medical explanation is more likely.
This is also why a quick talk with a lawyer can be more useful than weeks of comparing ads. A lawyer can often tell you which records to request first, whether a hidden-injury rule may help, whether the case should be screened for the MDL, and whether there are clear deadline concerns. None of that guarantees a viable lawsuit. But it can help you avoid mistakes while the claim may still be preserved.
What You Can Do Right Now
If this topic applies to you or your family, start with practical steps. These actions are often more useful than reading law firm ads.
- Save every imaging report and operative record you already have.
- Request your Depo-Provera shot history from the prescribing provider or pharmacy.
- Avoid guessing about deadlines based on social media posts or settlement rumors.
- Use the Do I Qualify? page to organize the facts before an intake call.
- Schedule a lawyer consult if you have a diagnosis and a documented history of use.
Frequently Asked Questions
Can you still file a Depo-Provera lawsuit in 2026?
Possibly. The litigation is active in 2026, but whether a new claimant can still file depends mostly on state deadline rules. Diagnosis timing and discovery-rule arguments matter too. Active litigation does not mean every late claim is timely.
Do you need a cancer diagnosis to qualify?
Not necessarily. Many lawsuits focus on meningioma. It is often not classified as a malignant brain cancer. What matters more is the diagnosis, treatment history, symptoms, and the legal theory available under the facts of the case.
Does using Depo-Provera automatically mean it caused a meningioma?
No. Current studies support a link. Current labeling also warns about a possible increased risk for growth of a meningioma. But individual causation still has to be proved with medical and expert evidence.
How long do you need to have used Depo-Provera before a lawyer will review the case?
There is no universal minimum in the law. Many screenings look more closely at repeated or prolonged use. That is because the published studies point to a stronger link in longer exposures.
Conclusion
The Depo-Provera litigation is real and active. It deserves serious attention from anyone who used the drug and was later diagnosed with meningioma. But the strongest next move is not to rely on headlines, rumor, or settlement talk. Document your use, preserve medical proof, and get a case-specific deadline review. If you were diagnosed after Depo-Provera, start the process at Do I Qualify? so you can sort out whether you may be entitled to take the next legal step.
This article provides general legal information. It is not legal advice. Filing deadlines, causation standards, and available damages vary by state and by the facts of each case. For legal advice about your own situation, consult a licensed attorney in your state.